Structure Therapeutics Inc. ADR (GPCR)
NASDAQ: GPCRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GPCR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.15B
- EPS (TTM)
- -$3.90
- Dividend yield
- None
- 52-week range
- 16.06 – 94.90
- Day range
- 16.08 – 17.08
- Volume / Avg
- 786.13K / 1.18M
- Beta
- —
- Shares outstanding
- 71.59M
52-week range
GPCR stock today
Shares of Structure Therapeutics (GPCR) finished lower on Nov 20 at $16.13, a drop of 5.78% or $0.99 per share, versus the S&P 500's 3.70% decline. At this level, GPCR sits near the bottom of its 52-week range of $16.06 to $94.90: 83.0% below the high, set on Dec 8, 2025 and 0.4% above the low. GPCR is down 76.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 53.0%.
Structure Therapeutics has posted a net loss over the last twelve months (EPS of -$3.90), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Structure Therapeutics
Company profileStructure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Raymond C. Stevens Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 281
- IPO year
- 2023
- Website
- structuretx.com
Financial highlights
Full financialsStructure Therapeutics reported a net loss of $141.2 million, compared with a loss of $122.5 million a year earlier. Diluted earnings per share came in at -$0.80.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Growth | — | — | — | — |
| Net income | $-141.20M | $-122.53M | $-89.62M | $-51.32M |
| EPS (diluted) | $-0.80 | $-0.78 | $-0.81 | $-5.51 |
Analyst forecast
ForecastConsensus (16 analysts)
strong_buy
Avg. price target
$104.86+550.09%
- Strong buy 4
- Buy 11
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.66 vs $-0.51
- Surprise
- -29.41%
GPCR news
All GPCR news- 4 Key Stocks to Watch Across Diabetes and Obesity This Awareness DayNasdaqNVO, LLY, VKTX, GPCR
- Will Wegovy Pill Drive Renewed GLP-1 Growth Momentum for Novo Stock?NasdaqNVO, LLY, VKTX, GPCR
- Structure Therapeutics Reports Third Quarter 2026 Financial ResultsNasdaq
- Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent HighlightsGlobeNewswire
- Novo Up 4% in a Month: How Should Investors Approach the Stock Now?NasdaqNVO, LLY, VKTX, GPCR
- Structure Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswire
- Novo Before Q3 Earnings: How Should Investors Play the Stock?NasdaqNVO, LLY, VKTX, GPCR
- Buy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 EarningsNasdaqLLY, NVO, VKTX, GPCR
Structure Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OPKOPKO Health Inc. | 1.57 | -2.48% | $1.17B | vs GPCR |
| HROWHarrow Inc. | 30.41 | -5.35% | $1.14B | vs GPCR |
| CMPSCOMPASS Pathways Plc American Depository Shares | 8.05 | -6.94% | $1.14B | vs GPCR |
| AAPGAscentage Pharma Group International American Depository Shares | 11.97 | -3.78% | $1.12B | vs GPCR |
| GHRSGH Research PLC | 17.53 | -5.55% | $1.20B | vs GPCR |
| AMPHAmphastar Pharmaceuticals Inc. | 28.25 | +0.50% | $1.20B | vs GPCR |
| MLYSMineralys Therapeutics Inc. | 13.66 | -3.53% | $1.21B | vs GPCR |
| OCULOcular Therapeutix Inc. | 5.57 | -4.95% | $1.23B | vs GPCR |
Indexes, lists and sector
Structure Therapeutics stock FAQ
What is Structure Therapeutics's stock price today?
GPCR last traded at $16.13 as of Nov 20, 4:00 PM EST, down 5.78% on the day. Prices are delayed at least 15 minutes.
Who is Structure Therapeutics's CEO?
Dr. Raymond C. Stevens Ph.D. is the chief executive officer of Structure Therapeutics Inc. ADR, which has about 281 employees.
What is the GPCR 52-week high?
The 52-week high for GPCR is $94.90 and the 52-week low is $16.06. The stock is currently 83.0% below its high.